Pancreatic Cancer Research

ResearcherKagawa UniversityNo recent work listed

Yoko Matsuda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3235-655X; OpenAlex author ID A5069983125. Sources: OpenAlex.

Their work

Papers
29 (first author 3, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
69
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 2 papers · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 6 papers · 2019: 7 papers · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers

Papers 29

  1. Silencing of tumoral carbohydrate sulfotransferase 15 reactivates lymph node pancreatic cancer T cells in mice. Last author DOI 10.1002/eji.202250160↗
  2. STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancr… Co-author DOI 10.1016/j.eclinm.2022.101731↗
  3. Pathologic Examination of Pancreatic Specimens Resected for Treated Pancreatic Ductal Adenocarcinoma: Recommendations From the Pancreatobiliary Pathology Socie… Co-author DOI 10.1097/pas.0000000000001853↗
  4. mAb Das-1 identifies pancreatic ductal adenocarcinoma and high-grade pancreatic intraepithelial neoplasia with high accuracy. Co-author DOI 10.1016/j.humpath.2021.01.003↗
  5. Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2021.09.006↗
  6. Adequate tissue sampling for the assessment of pathological tumor regression in pancreatic cancer. Last author DOI 10.1038/s41598-021-86152-y↗
  7. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression g… Co-author DOI 10.1038/s41598-020-74067-z↗
  8. FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pan… Co-author DOI 10.3390/cancers12102976↗
  9. Enhanced morphological and functional differences of pancreatic cancer with epithelial or mesenchymal characteristics in 3D culture. Co-author DOI 10.1038/s41598-019-47416-w↗
  10. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-019-53801-2↗
  11. Pancreatic cancer manifesting as Sister Mary Joseph nodule during follow up of a patient with type 2 diabetes mellitus: A case report. Co-author DOI 10.1111/ggi.13602↗
  12. Encapsulating fibrosis following neoadjuvant chemotherapy is correlated with outcomes in patients with pancreatic cancer. Co-author DOI 10.1371/journal.pone.0222155↗
  13. Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment. Last author DOI 10.3390/ijms20174224↗
  14. The stem cell-specific intermediate filament nestin missense variation p.A1199P is associated with pancreatic cancer. Co-author DOI 10.3892/ol.2019.10106↗
  15. Overexpression of carbohydrate sulfotransferase 15 in pancreatic cancer stroma is associated with worse prognosis. Co-author DOI 10.3892/ol.2019.10764↗
  16. Pancreatic cancer stem cells: features and detection methods. First author DOI 10.1007/s12253-018-0420-x↗
  17. Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreati… Co-author DOI 10.1016/j.gie.2017.10.030↗
  18. Reduced expression of the H19 long non-coding RNA inhibits pancreatic cancer metastasis. First author DOI 10.1038/s41374-018-0048-1↗
  19. Stemness and anti-cancer drug resistance in ATP-binding cassette subfamily G member 2 highly expressed pancreatic cancer is induced in 3D culture conditions. Co-author DOI 10.1111/cas.13533↗
  20. H19 long non-coding RNA contributes to sphere formation and invasion through regulation of CD24 and integrin expression in pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.26176↗
  21. Electron microscopic analysis of different cell types in human pancreatic cancer spheres. Co-author DOI 10.3892/ol.2017.7554↗
  22. Nestin phosphorylation at threonines 315 and 1299 correlates with proliferation and metastasis of human pancreatic cancer. Co-author DOI 10.1111/cas.13139↗
  23. Systemic Administration of Small Interfering RNA Targeting Human Nestin Inhibits Pancreatic Cancer Cell Proliferation and Metastasis. Co-author DOI 10.1097/mpa.0000000000000427↗
  24. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion. Co-author DOI 10.3892/or.2016.4727↗
  25. Nestin delineates pancreatic cancer stem cells in metastatic foci of NOD/Shi-scid IL2Rγ(null) (NOG) mice. Co-author DOI 10.1016/j.ajpath.2013.11.014↗
  26. Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer. Co-author DOI 10.1111/cas.12470↗
  27. Nestin regulates epithelial-mesenchymal transition marker expression in pancreatic ductal adenocarcinoma cell lines. First author DOI 10.3892/mco.2012.1↗
  28. Nestin and other putative cancer stem cell markers in pancreatic cancer. Co-author DOI 10.1007/s00795-012-0571-x↗
  29. Nestin is a novel target for suppressing pancreatic cancer cell migration, invasion and metastasis. Co-author DOI 10.4161/cbt.11.5.14673↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tomio Arai · 14 shared papers, 2016–2023 · strength 1.30
  2. Toshiyuki Ishiwata · 17 shared papers, 2011–2020 · strength 1.26
  3. Hisashi Yoshimura · 9 shared papers, 2014–2020 · strength 0.69
  4. Norihiko Sasaki · 7 shared papers, 2018–2020 · strength 0.59
  5. Keiko Yamakawa · 4 shared papers, 2019–2023 · strength 0.54
  6. Junko Aida · 6 shared papers, 2018–2019 · strength 0.49
  7. Naohisa Yahagi · 3 shared papers, 2018–2023 · strength 0.44
  8. Mari A. Mino-Kenudson · 4 shared papers, 2019–2021 · strength 0.43
  9. Juanjuan Ye · 3 shared papers, 2021–2023 · strength 0.41
  10. Motohiro Kojima · 4 shared papers, 2019–2021 · strength 0.41
  11. Makoto Nishimura · 3 shared papers, 2018–2023 · strength 0.36
  12. Masashi Toyoda · 4 shared papers, 2018–2020 · strength 0.35
  13. Motohiko Kato · 2 shared papers, 2023 · strength 0.35
  14. Masanao Yokohira · 3 shared papers, 2019–2021 · strength 0.34
  15. Takao Itoi · 2 shared papers, 2018–2023 · strength 0.24
  16. Kenichi Hirabayashi · 2 shared papers, 2020–2021 · strength 0.22
  17. Yasuyuki Suzuki · 2 shared papers, 2021 · strength 0.22
  18. Keiichi Okano · 2 shared papers, 2021 · strength 0.22
  19. Zenya Naito · 4 shared papers, 2011–2016 · strength 0.20
  20. Fujiya Gomi · 2 shared papers, 2019–2020 · strength 0.19
  21. Shinichiro Takahashi · 2 shared papers, 2019–2020 · strength 0.19
  22. Murray Korc · 3 shared papers, 2011–2020 · strength 0.19
  23. Toshio Fujisawa · 1 shared paper, 2023 · strength 0.16
  24. Hiroyuki Isayama · 1 shared paper, 2023 · strength 0.16
  25. Kazuki Takakura · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.